VKTX
USDViking Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$36.740
Kõrge
$38.000
Madal
$34.615
Maht
3.77M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
3.9B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
6.60M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera has become the obesity drug market's hottest ticket.
Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106
Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics with a Buy rating and announces Price Target of $106.
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75
JP Morgan analyst Hardik Parikh maintains Viking Therapeutics with a Overweight and lowers the price target from $80 to $75.
Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102
Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics with a Overweight and raises the price target from $98 to $102.
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.